The producibility of interferon (IFN)‐α, which indicates one of the functions of large granular lymphocytes (LGL), was impaired at a high frequency in myelodysplastic syndrome (MDS) patients. However, IFN‐α production in refractory anaemia, which is a subtype of MDS, was almost normal. In contrast, abnormality has not been observed in either proliferative response or the production of IFN‐γ of T‐cells by stimulation with PHA. NK activity of peripheral blood mononuclear cells (PBMC) from MDS patients was generally low and was not augmented by IFN‐α treatment. These results indicate that, in addition to the abnormality at the level of haematopoietic tissues, LGL among PBMC may be impaired in MDS patients.
Summary We assessed the origin of bone marrow derived fibroblastoid cells (BMF) in long‐term cultures of 13 samples obtained from nine patients after allo‐BMT by polymerase chain reaction (PCR) amplification of MCT118, one of the variable number of tandem repeats regions (VNTR). BMF showed a complete recipient pattern in nine samples obtained from seven patients; however, a recipient‐predominant mixed chimaeric pattern was detected in BMF from four patients. Also, two of the four patients died with bone marrow hypoplasia. These data suggest that mixed chimaeric pattern of BMF may be correlated with bone marrow hypoplasia.
It was studied whether the abnormal fibrinogen could be existed in umbilical cord blood as compared with hepatoma associated dysfibrinogen.The plasma and purified fibrinogen of patients (12 cases of cord blood and 16 cases of hepatoma) were studied as follows, [1] with plasmaFibrin monomer polymerization were estimated with Soria's method.[2] with purified fibrinogen(1) thrombin time(2) reptilase time(3) fibrin monomer polymerization(4) SDS-PAGE(5) immunoelectrophoresis(6) content of sialic acidUsing with plasma, fibrin monomer polymerization of both cord blood group and hepatoma group were markedly decreased. Using with purified fibrinogen, thrombin time and reptilase time were prolonged in hepatoma group, but not in cord blood group.The content of sialic acid of fibrinogen in hepatoma was increased, but not marked in cord blood.On mobility of electrophoresis, the difference was no noticed between two groups.
Reverse transcriptase-polymerase chain reaction showed that interleukin 3, IL-4, IL-5, IL-6, interferon-gamma and stem cell factor mRNA expression were higher in 15-deoxyspergualin-treated spleen cells than in control spleen cells. Increased IL-2 and IFN-gamma mRNA expression were observed in 15-deoxyspergualin-treated bone marrow cells. On the other hand, increased platelet counts in BALB/c-->C3H/He bone marrow chimeras were observed from days 20 to 33 in our previous work, when they were treated with 15-deoxyspergualin from days 14 to 25. In contrast, marked leukocytopenia and anemia were simultaneously observed, although a marked leukocytosis and a rapid recovery of anemia were observed on day 33 and thereafter. To analyze effects of 15-deoxyspergualin on hematopoiesis and the immune system, we examined mRNA expression in bone marrow and spleen cells from BALB/c-->C3H/He bone marrow chimeras treated with 15-deoxyspergualin from days 14 to 25. Reverse transcriptase-polymerase chain reaction showed that IL-3, IL-4, IL-6, stem cell factor, granulocyte colony-stimulating factor, and granulocyte/macrophage colony-stimulating factor mRNA expression were higher in 15-deoxyspergualin-treated chimeras than in control chimeras, indicating that these cytokines are responsible for an enhancement of hematopoiesis. It was conceivable that IL-6 supported thrombopoiesis in concert with other cytokines. On the contrary, increased IFN-gamma, IL-2, IL-3, IL-4, and IL-10 mRNA expression may play an immunosuppressive role in vivo.
Serum soluble c-kit concentrations were measured in 28 patients undergoing bone marrow transplantation (BMT). The c-kit levels in patients with delayed engraftment (time to leukocyte recovery > 1.0 × 109/L being more than 20 days after BMT) were significantly lower than those in patients with early engraftment (time to leukocyte recovery being less than 19 days after BMT) from the start of conditioning until day 100 after BMT. The data from this study indicates that the measurement of serum soluble c-kit concentrations may be a useful indicator of engraftment.
beta-Glucuronidase purified from human placenta and chronic myelogenous leukemic cells was composed of three components of 18, 64 and 80 kDa, though the relative contents of the components were different between the sources. Analysis of their N-terminal amino-acid sequences showed that the 18-kDa and 64-kDa components were derived from the 80-kDa component by cleavage between Val159 and Gly160. Furthermore, the enzyme was found to be glycosylated at Asn173 and Asn420 with high mannose-type oligosaccharides, based on the electrophoretic mobility of the components as well as the endopeptidic peptides before and after endoglycosidase treatment. The enzyme purified from leukemic cells was poorly phosphorylated by N-acetylglucosamine 1-phosphotransferase as compared to the placental enzyme.
We investigated the effects of 8-(N, N-diethylamino)-octyl-3, 4, 5-trimethoxybenzoate (TMB-8), intracellular calcium antagonist, and diltiazem, calcium entry blocker, on platelet activation and cytosolic free Ca2+ concentration ([Ca2+]cyt) in platelets.In control, resting [Ca2+]cyt level was 64.6±11.1nM, and 0.5U/ml thrombin-stimulated [Ca2+]cyt was increased to 223.0±32.0nM in the medium containing 0.2mM CaCl2. TMB-8 (0.05mM, 0.1mM, 0.2mM) and diltiazem (0.1mM, 0.2mM, 0.4mM) didn't alter resting [Ca2+]cyt but inhibited thrombin-activated [Ca2+]cyt in a dose-dependent manner. Both drugs also inhibited thrombin-induced platelet aggregation, as well as [Ca2+]cyt. However, they little influenced 14C-serotonin release and 45Ca2+ uptake. There seems to be some particular mode of inhibition, that is, TMB-8 suppresses the rapid phase, and diltiazem suppresses the delayed phase of increase in [Ca2+]cyt stimulatedby thrombin.